Processing...
Clinical Trials for Small Cell Lung Cancer
Search
Search
There are 464 active trials for advanced/metastatic small cell lung cancer.
Click on a trial to see more information.
464 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Adults with homozygous MTAP-deleted solid tumors (ECOG 0–1) receive oral BAY 3713372, an MTAP-selective, second-generation PRMT5 inhibitor exploiting synthetic lethality, with monotherapy dose escalation and expansions in all MTAP-deleted tumors plus focused cohorts in NSCLC and PDAC. Expansion includes BAY 3713372 alone and in combinations for NSCLC and PDAC; key cardiac comorbidities are excluded.
ClinicalTrials.gov ID: NCT06914128
TrialFetch AI summary: Adults with FRα-positive metastatic/recurrent lung adenocarcinoma and malignant pleural effusion (ECOG 0–1, prior systemic therapy) receive cyclophosphamide/fludarabine lymphodepletion followed by a single intrapleural infusion of autologous MOv19-BBz CAR T cells targeting folate receptor‑alpha (second‑generation CAR with 4‑1BB/CD3ζ). Candidates must be eligible for standard checkpoint inhibitors (which may start ≥28 days post‑CAR T) and have controlled CNS disease; key exclusions include extensive parenchymal lung involvement beyond one lobe, significant undrainable effusion, ILD/pneumonitis, active hepatitis, and autoimmune disease requiring immunosuppression.
ClinicalTrials.gov ID: NCT07116057
TrialFetch AI summary: Adults with previously treated, locally advanced/metastatic small cell lung cancer or other neuroendocrine tumors (e.g., LCNEC, NEPC, high‑grade GI‑NET, Merkel cell) receive BL‑M14D1, an investigational DLL3‑targeted antibody–drug conjugate with a topoisomerase I inhibitor payload, given IV every 21 days. Suitable for ECOG 0–1 patients post‑standard therapy (SCLC requires prior platinum); excludes prior topo‑I ADCs, significant cardiac/QTc issues, ILD/pneumonitis, active CNS disease, and uncontrolled infections.
ClinicalTrials.gov ID: NCT07080242
TrialFetch AI summary: Adults with DLL3-expressing advanced solid tumors, including previously treated SCLC or LCNEC (dose escalation) and expansion cohorts of SCLC (≤2 prior lines), de novo or treatment-emergent NEPC, and GEP-NEC; some cohorts require demonstrable uptake on 111In-ETN029 SPECT. Single-arm therapy with 225Ac-ETN029, a DLL3-targeted alpha-emitting radiopharmaceutical delivering actinium-225 to tumor cells, with optional 111In-ETN029 imaging/dosimetry.
ClinicalTrials.gov ID: NCT07006727
TrialFetch AI summary: Adults with extensive-stage SCLC that has progressed after ≥1 prior systemic therapy, including those with controlled brain metastases, receive tarlatamab (DLL3-directed bispecific T‑cell engager) combined with AB248 (CD8-targeted IL‑2 mutein fusion designed to selectively activate CD8+ T cells) to assess safety, dose, and preliminary efficacy. Excludes prior DLL3- or IL‑2/7/15–directed therapies and symptomatic CNS disease.
ClinicalTrials.gov ID: NCT07037758
TrialFetch AI summary: Adults with locally advanced or metastatic DLL3-expressing tumors—primarily relapsed/refractory SCLC after ≥2 prior systemic lines including platinum and immunotherapy (or not suitable for standard 2L), plus previously treated lung LCNEC and extrapulmonary neuroendocrine carcinomas—are eligible (measurable disease; stable CNS mets allowed), with DLL3 positivity confirmed by [203Pb]Pb-DOTAM-MAM279 SPECT/CT in specified cohorts. Participants receive [203Pb]Pb-DOTAM-MAM279 imaging/dosimetry followed by therapeutic [212Pb]Pb-DOTAM-MAM279 (MP0712), a DLL3-targeted DARPin radiopharmaceutical delivering alpha-emitting lead-212 to DLL3-expressing tumor cells.
ClinicalTrials.gov ID: NCT07278479
TrialFetch AI summary: Adults (ECOG 0–1) with refractory/recurrent locally advanced or metastatic solid tumors—particularly tissue factor–expressing cancers such as HNSCC, NSCLC, esophagogastric, colorectal, pancreatic ductal adenocarcinoma, cervical, endometrial, or urothelial carcinoma—after appropriate prior systemic therapy (prior-line limits vary by study part) are eligible. Treatment is STRO-004, a tissue factor–targeting antibody–drug conjugate delivering an exatecan (topoisomerase I inhibitor) payload, given as monotherapy with dose escalation/expansion or combined with pembrolizumab (PD-1 inhibitor).
ClinicalTrials.gov ID: NCT07227168
TrialFetch AI summary: Enrolls adults with relapsed/refractory locally advanced or metastatic solid tumors harboring a SMARCA4 loss-of-function mutation (ECOG 0–1, measurable disease) after progression on, intolerance of, or ineligibility for standard approved therapies. Patients receive oral once-daily PLX-61639, a SMARCA2 targeted protein degrader (synthetic-lethal strategy in SMARCA4-deficient tumors; DCAF16-linked, proteasome-mediated SMARCA2 degradation).
ClinicalTrials.gov ID: NCT07284186
TrialFetch AI summary: Adults with locally advanced unresectable or metastatic solid tumors harboring a KRAS alteration (mutation or amplification) who have progressed on, are ineligible for, or declined standard-of-care therapy (Arm D additionally requires PD-L1 TPS ≥50%; excludes untreated CNS metastases and ILD/pneumonitis). Participants receive the first-in-human agent BMS-986523 (target/mechanism not publicly described) as monotherapy or combined with pembrolizumab (anti–PD-1), cetuximab (anti-EGFR), or gemcitabine plus nab-paclitaxel.
ClinicalTrials.gov ID: NCT07223047
TrialFetch AI summary: Adults with locally advanced/metastatic measurable solid tumors harboring any KRAS mutation or wild-type KRAS amplification (ECOG 0–1) after 1–4 prior systemic regimens are treated with IV PT0511 monotherapy in dose-escalation/expansion cohorts; a colorectal cancer expansion cohort receives PT0511 plus cetuximab (anti-EGFR). PT0511 is an investigational KRAS-altered tumor–directed agent, but its specific molecular mechanism/allele selectivity is not publicly specified.
ClinicalTrials.gov ID: NCT07300150